Anti–αv Integrin Monoclonal Antibody Intetumumab Enhances the Efficacy of Radiation Therapy and Reduces Metastasis of Human Cancer Xenografts in Nude Rats

Shoucheng Ning¹, Junqiang Tian¹, Deborah J. Marshall², and Susan J. Knox¹

Abstract
We previously reported that intetumumab (CNTO 95), a fully human anti–αv integrin monoclonal antibody, is a radiosensitizer in mice with xenograft tumors. Because intetumumab does not cross-react with mouse integrins, but has cross-reactivity with rat integrins, we next studied the potential combined use of radiation therapy and intetumumab in human cancer xenograft models in nude rats to assess effects on both tumor cells and the tumor microenvironment. Nude rats bearing human head and neck cancer and non–small-cell lung cancer (NSCLC) xenografts were treated with intetumumab and fractionated local tumor radiotherapy. Effects on tumor growth and metastasis, blood perfusion, oxygenation, and gastrointestinal toxicity were studied. Intetumumab alone had a moderate effect on tumor growth. When combined with fractionated radiation therapy, intetumumab significantly inhibited tumor growth and produced a tumor response rate that was significantly better than with radiation therapy alone. Treatment with intetumumab also significantly reduced lung metastasis in the A549 NSCLC xenograft model. The oxygenation and blood perfusion in xenograft tumors measured by microbubble-enhanced ultrasound imaging were substantially increased after treatment with intetumumab. The combined use of intetumumab and radiation therapy reduced the microvessel density and increased apoptosis in tumor cells and the tumor microenvironment. Toxicity studies showed that treatment with intetumumab did not cause the histopathologic changes in the lungs and did not sensitize the sensitive gastrointestinal epithelium to the effect of radiation therapy. Intetumumab can potentiate the efficacy of fractionated radiation therapy in human cancer xenograft tumors in nude rats without increased toxicity.

Cancer Res; 70(19); OF1–9. ©2010 AACR.

Introduction
Intetumumab (CNTO 95) is a fully human anti–αv integrin monoclonal antibody that binds human αv integrin–expressing cells with high affinity (Kd, approximately 1–24 nmol/L) and has limited cross-reactivity with rat αv integrin (Kd, 220 nmol/L; ref. 1). Preclinical studies have shown that intetumumab exhibits antiangiogenic and anti–tumor activity in human cancer xenograft models in nude mice (1–3). Intetumumab has been reported to inhibit cell adhesion, migration, invasion, and proliferation of endothelial cells and tumor cells in vitro and tumor metastasis in vivo in nude mice with human breast cancer xenografts by inactivating the focal adhesion kinase (FAK) and the docking protein paxillin (1, 4). We have previously shown that intetumumab is a potential radiation sensitizer when used in combination with fractionated radiation therapy in human cancer xenograft models in nude mice (5). Data from two multicenter clinical phase I studies in patients with advanced solid tumors have shown that intetumumab was safe and well tolerated either alone or in combination with docetaxel (6, 7). Intetumumab is now in phase II clinical trials for the treatment of a variety of malignancies.

Although the specific mechanism of action responsible for the antitumor activity of intetumumab has been not fully elucidated, inhibition of tumor angiogenesis via inhibitory effects on targeted integrins is thought to play an important role in the inhibition of tumor growth. However, the antitumor and antimetastatic activities of intetumumab observed in nude mice with human cancer xenografts are most likely independent of its antiangiogenic activity because intetumumab does not cross-react with mouse αv integrins. In fact, intetumumab was more potent in inhibiting tumor growth in nude rats than in nude mice with the same human melanoma xenografts (1). To fully assess the effects of intetumumab on radiation response of tumors and interaction of tumor cells and their microenvironments, we next studied the combined use of intetumumab and fractionated local tumor radiation therapy in nude rats with human cancer xenograft. Based on our previous studies (5, 8, 9), we hypothesized that intetumumab would potentiate the efficacy of fractionated radiation therapy.
therapy and inhibit tumor metastasis by blocking the function of adhesion molecules in the microenvironment of potential metastatic sites.

**Materials and Methods**

**Antibodies**

Intetumumab (CNTO 95) was provided by Centocor, Inc. Intetumumab was diluted in physiologic saline (0.9% sodium chloride) at a concentration of 1.0 mg/mL for i.p. injection.

**Cell culture**

Human head and neck cancer cell lines FaDu and non–small cell lung cancer (NSCLC) cell line A549 were obtained from the American Type Culture Collection. Cells were maintained in DMEM (Invitrogen) supplemented with 10% FCS, 100 units/mL penicillin, and 100 µg/mL streptomycin in a 37°C humidified incubator with a mixture of 95% air and 5% CO₂. All experiments were performed on exponentially growing cells with a cell population doubling time of approximately 24 to 36 hours. The identity of cells has regularly been confirmed throughout the course of the studies by observation of the growth pattern and cell morphology in vitro and in vivo.

**Rat tumor model and therapy**

Male nude rats, 5 to 6 weeks old and 150 to 200 g in body weight, were purchased from Harlan Laboratories. Rats were tested and found to be negative for specific pathogens. The rats were normally bred and maintained under specific pathogen-free conditions, and sterilized food and water were available ad libitum. Rats were injected s.c. in the right flank with $5 \times 10^6$ tumor cells in a suspension volume of 0.1 mL. One tumor per rat was inoculated. When tumors reached an average size of 200 mm³ (150–250 mm³), rats were randomly assigned to the different treatment groups. Intetumumab was injected i.p. at a dose of 10 mg/kg body weight, once weekly until completion of the study, or as specified in each experiment. In combination therapy, intetumumab was injected 30 to 60 minutes before irradiation. For irradiation, the anesthetized tumor-bearing rats were placed in individual lead boxes with tumors protruding through a cutout window at the rear of each box. The radiation was delivered using a Philips RT-250 200 kVp X-ray unit (12.5 mA; half-value layer, 1.0-mm Cu) at a dose rate of 140 cGy/min. Tumors were locally irradiated with a dose of 250 cGy per fraction daily for 5 consecutive days. In some experiments, a single dose of irradiation was used as specified in each experiment. The length and width of the tumors were measured with calipers before treatment, and three times a week thereafter until the tumor volume reached at least four times the pretreatment volume. The tumor volume was calculated using the formula: tumor volume (mm³) = $\pi/6 \times$ length $\times$ width². The response of tumors to the treatment is defined as complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). A CR of tumors was recorded if a tumor completely disappeared and was not palpable at the end of the experiment (or 30 days after completion of radiation therapy). A PR was a reduction in volume of ≥50% compared with the initial tumor volume at the start of treatment. SD was defined as the tumor size neither PR nor PD criteria met. PD was an increase in tumor volume of ≥20% of the pretreatment volume. Body weight of animals was measured three times a week. The animal experiments described herein were approved by the Stanford University Administrative Panel for Laboratory Animal Care.

**Lung metastasis models**

We studied the lung metastasis of tumors using two different tumor metastasis models: an i.v. injection model and a s.c. tumor model. In the i.v. injection model, nude rats were injected with $1 \times 10^6$ A549 cells in 0.2-mL Hank’s solution via the lateral tail vein. Immediately after tumor cell injection, rats were randomly assigned to two groups. One group of nine rats was injected i.p. with 10 mg/kg intetumumab, once a week for 60 days. A second group of 10 rats was injected with physiologic saline (10 mL/kg), once weekly for 60 days. In the s.c. tumor model, nude rats were inoculated s.c. in the right flank with $5 \times 10^6$ A549 cells, with one tumor site per rat. When tumors reached an average size of 200 mm³, rats were randomly assigned to one of four treatment groups and treated as described above in the Rat tumor model and therapy section. After 60 days, rats were euthanized and the lungs were immediately removed and fixed in either Bouin’s solution or 10% buffered formalin for counting of pulmonary metastatic nodules.

**Immunohistochemistry analysis**

General histopathologic changes, apoptosis, and microvessel density of tumors were assessed by immunohistochemical staining. Tumor-bearing rats were euthanized 3 days after treatment for tumor collection with three rats per treatment regimen. Harvested tumors were immediately frozen in OCT compound, sectioned at 8-µm thickness, and stained with H&E for general histopathologic analysis, with an ApopTag peroxidase in situ oligo ligation (ISOL) apoptosis detection kit (Chemicon International) for detection of apoptosis, and with an anti-CD31 polyclonal antibody (Santa Cruz Biotechnology) for microvessel density counts. Slides were counterstained with hematoxylin for background nuclear visualization. Slides were visualized and photographed using a Leica DM6000B fluorescence/light microscope (Leica Microsystems). For quantification of microvessels, tissue sections were analyzed at ×40 magnification and CD31-positive vessels were counted. Four fields per section were randomly analyzed, and data are presented as the mean ± SD of three tumors.

**Assessment of tumor hypoxia**

Tumor hypoxia was assessed using the hypoxia marker EF5 as previously described (10). Briefly, 3 days after treatment with a single dose of 10 mg/kg intetumumab or 5 Gy irradiation alone, or in combination, rats bearing FaDu tumors were injected with 10 mmol/L EF5 solution. Two hours later, tumors were collected, frozen in liquid nitrogen, sectioned, and stained with anti-EF5 antibody ELK3-51 conjugated with...
Cy3. Digital photomicrographs were taken at ×40 magnification with a fluorescence microscope. The Cy3 signal was analyzed with Adobe Photoshop program. The EF5 binding due to hypoxia was determined by correction for nonspecific and endogenous binding.

Microbubble-enhanced ultrasound image

Two days after treatment, tumor-bearing rats were imaged on a Vevo 770 system (VisualSonics, Inc.) with a 40-MHz transducer. Rats were anesthetized with a 3% isoflurane-oxygen mixture, and the body temperature was monitored and maintained at 37°C on a warming plate during the imaging session. The coupling gel was applied to the skin over the tumor, and a 12 × 12-mm view field was imaged by two-dimensional contrast mode. A baseline image was acquired before microbubble injection. The contrast-enhanced image was acquired 5 seconds after a bolus injection of the non-targeted microbubble contrast agent (3 × 10⁸ microbubbles/0.1 mL) via a tail vein catheter. Images were acquired at 20 frames per second for a total of 800 frames. The image data were analyzed using Vevo 770 Contrast Mode software by comparing the contrast cine loop with the baseline cine loop to generate a contrast overlay to identify the differences in image intensity between these two loops.

Intestinal crypt stem cell assay

Nude rats were divided into two groups. One group of rats was injected i.p. with a single dose of 10 mg/kg intetumumab 1 hour before irradiation. Rats were irradiated with a total body irradiation (TBI) at doses of 10 to 15 Gy. There were three rats per dose point per group. Three days following irradiation, rats were euthanized. The duodenum, jejunum, and ileum were immediately removed and fixed in 10% buffered formalin. The intestinal segments were cut into four pieces, embedded in paraffin, sectioned, and stained with H&E. Surviving crypts (≥10 cells) for each cross-section were counted by light microscopy. Each viable crypt is presumed to contain one or more surviving intestinal crypt stem cells. Eight cross-sections were scored per segment. The results are presented as mean crypt cell numbers per cross-section ± SD.

Statistics

Data were statistically analyzed using a two-tailed Student’s t test.

Results

Effect of intetumumab on tumor responses to local fractionated radiation therapy

Nude rats with established FaDu and A549 xenograft tumors were treated with (a) 10 mg/kg intetumumab, once a week; (b) 250 cGy radiation daily for 5 days; (c) a combination of intetumumab and radiation as above; or (d) an i.p. injection of normal saline (0.01 mL/g body weight) once weekly as an untreated control. Data are shown in Table 1 and Fig. 1. Treatment with intetumumab alone, radiotherapy alone, or in combination inhibited tumor growth and produced complete regression of tumors in both FaDu and A549 tumor models. The total tumor response rates (CR and PR) were 33%, 67%, and 89% in FaDu tumor model and 17%, 17%, and 67% in A549 tumor model for intetumumab alone, radiation alone, and combination therapy, respectively. The combination treatment was more effective in inhibiting tumor growth and resulted in complete regression of tumors in seven of nine rats with FaDu tumors and four CRs of six rats with A549 tumors, which was significantly higher than the other treatment regimens studied (P < 0.05). In addition, tumors with a PR and no response (SD and PD) to the treatment grew slower following combined therapy than those treated with either intetumumab or radiation alone (Fig. 1).

Intetumumab alone or in combination with radiation did not cause any significant decrease in body weight compared with untreated control animals (data not shown). There were no obvious change in the general appearance, skin reaction, or daily activity of tumor-bearing rats treated with intetumumab either alone or in combination with radiation. H&E staining of the lungs showed that there were no obvious changes in histopathology in lungs from rats treated with either intetumumab or radiation alone (Fig. 1).

Table 1. Therapeutic responses of FaDu and A549 xenograft tumors in nude rats

<table>
<thead>
<tr>
<th>Tumor model</th>
<th>No. of animals</th>
<th>Tumor response</th>
<th>CR + PR (% total)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FaDu</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Untreated control</td>
<td>9</td>
<td>1</td>
<td>8</td>
</tr>
<tr>
<td>Intetumumab alone</td>
<td>9</td>
<td>3</td>
<td>6</td>
</tr>
<tr>
<td>Radiation alone</td>
<td>9</td>
<td>6</td>
<td>3</td>
</tr>
<tr>
<td>Intetumumab + radiation</td>
<td>9</td>
<td>7</td>
<td>1</td>
</tr>
<tr>
<td>A549</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Untreated control</td>
<td>6</td>
<td>6</td>
<td>0</td>
</tr>
<tr>
<td>Intetumumab alone</td>
<td>6</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>Radiation alone</td>
<td>6</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Intetumumab + radiation</td>
<td>6</td>
<td>4</td>
<td>2</td>
</tr>
</tbody>
</table>

NOTE: CR, complete disappearance of tumors on day 30; PR, ≥50% decrease in tumor volume on day 30; SD, no significant change in tumor volume on day 30; PD, ≥20% increase in tumor volume on day 30.

Effect of intetumumab on tumor metastasis

Next, we studied the effects of intetumumab on the lung metastasis of A549 xenograft tumors using an i.v. injection model for testing the homing ability of lung cancer cells and a s.c. tumor model for testing the spontaneous metastasis to lung. Data are shown in Fig. 2. There were significant differences in the number of rats with metastatic lung lesions and the mean number of metastatic lesions per lung between

Intetumumab either alone or in combination with radiation compared with untreated control animals.
the intetumumab-treated group and the untreated control group. Sixty days after an i.v. injection of A549 cells, 9 of 10 rats developed metastatic lung lesions in the untreated control group, whereas only 4 of 9 rats developed lung metastases in the intetumumab-treated group ($P < 0.05$). The average number of metastatic lesion per lung was $56 \pm 50$ (with a range of 3–142) in the control group and $13 \pm 8$ (with a range of 6–24) in the intetumumab-treated group ($P = 0.02$).

In the s.c. tumor model, treatment with intetumumab alone or in combination with local tumor radiation inhibited spontaneous lung metastasis of A549 tumors and decreased both the number of rats with lung metastasis and the number of metastatic lesions per lung (Fig. 2). The average number of metastatic lesions per lung was $18 \pm 9, 6 \pm 2, 12 \pm 9$, and $4 \pm 2$ for groups treated with normal saline (control), intetumumab alone, radiation alone, and the combination of intetumumab and radiation, respectively.

**Effect of intetumumab on apoptosis, microvasculature, oxygenation, and blood perfusion of xenograft tumors**

To understand the mechanism of action by which intetumumab enhances the efficacy of radiation therapy, we studied apoptosis, microvessel density, oxygenation, and blood perfusion in xenograft tumors using immunohistochemical staining (Fig. 3) and microbubble-enhanced micro-ultrasound imaging (Fig. 4).

The apoptotic cell death in tumors was assessed using the ApopTag peroxidase ISOL apoptosis detection staining. In the untreated control, 9 ± 3 for intetumumab alone, 52 ± 5 for radiation alone, and 116 ± 12 for the combination of intetumumab and radiation ($P < 0.01$, combination versus all other groups), respectively.

CD31 staining showed that intetumumab alone did not significantly affect the number of CD31-positive microvessels compared with untreated control tumors (28 ± 2 per field for control and 25 ± 5 per field for intetumumab alone; $P = 0.3$), but morphologically, vessels in intetumumab-treated tumors were more regular and distributed more uniformly than seen in untreated control tumors. Radiation therapy reduced the number of CD31-positive microvessels to $13 \pm 2$ per field (a 54% decrease; $P = 0.03$ versus control). The combination of radiation and intetumumab further reduced the number of tumor microvessels to $6 \pm 2$ per field, representing a further 54% decrease ($P = 0.02$ versus radiation alone). Morphologically, the microvessels were much less regular and shorter and had more closed ends in tumors treated with radiation, either alone or in combination with intetumumab.

Results of EF5 staining showed that tumors from untreated rats had the highest level of EF5 staining, and tumors from rats treated with the combination of intetumumab and radiation had the lowest level of hypoxia. EF5-stained hypoxic regions were decreased by 40% in tumors treated with intetumumab alone and by 54% in tumors treated with intetumumab and radiation compared with untreated control tumors ($P = 0.01$). The quantification of EF5 staining showed that the EF5 signal intensity was $59 \pm 6\%$ that of control tumors in intetumumab-treated tumors, $72 \pm 8\%$ in radiation-treated tumors, and $46 \pm 6\%$ in tumors treated with intetumumab plus radiation.

To further examine whether the reduction of hypoxia was due to the improvement of blood perfusion in tumors, we assessed the blood perfusion and blood volume in tumors using microbubble-enhanced ultrasound imaging. Figure 4 shows signal intensity as a function of image frame (time), with the slope of the curve representing the relative rate of blood perfusion and the plateau representing the relative blood volume in the tumors. Treatment with intetumumab...
dramatically increased the rates of blood perfusion and blood volume of tumors. Radiation alone did not increase the perfusion rate. When combined with intetumumab, the perfusion rate and blood volume in tumors were significantly enhanced.

Meanwhile, H&E staining revealed many more large and diffuse areas of necrosis in tumors treated with radiation, either alone or in combination with intetumumab. There was no apparent difference in the H&E staining of intetumumab-treated tumors and untreated control tumors.

**Effect of intetumumab on the sensitivity of intestinal crypt stem cells to radiation—gastrointestinal toxicity study**

Gastrointestinal toxicity caused by radiation limits the therapeutic dose that can be used for treating abdominal and pelvic tumors with radiation therapy. This toxicity is primarily due to the killing of the crypt stem cells in the intestinal epithelium. We performed experiments to study the effect of intetumumab on irradiated intestinal crypt cell survival. The results are shown in Fig. 5. Intetumumab alone had no effect on crypt cell growth and proliferation. For radiation, there was a dose-dependent decrease in the crypt stem cells in the duodenum, jejunum, and ileum after a single dose of 10 to 15 Gy TBI. Administration of intetumumab slightly decreased the mean number of surviving crypt cells at radiation doses above 13 Gy. However, the decrease in the mean number of crypt cells was not significantly different when compared with similarly irradiated control rats without intetumumab treatment ($P > 0.05$).

**Discussion**

We previously reported that intetumumab sensitized human xenograft tumors to radiation in mice (5). Intetumumab does not bind to mouse $\alpha v$ integrins, so this observed effect was due to direct effects of the antibody on the tumor cells, as well as to possible indirect effects of the intetumumab-treated tumor cells on the surrounding vasculature and microenvironment. Therefore, the use of mouse models for these studies was suboptimal because they did not allow for assessment of the direct effect of the antibody on both tumors and tumor vasculature in the tumor microenvironment when combined with radiation. Intetumumab does
cross-react with rat integrins, so to better study the combined effect of intetumumab and radiation in a more clinically relevant model, we used nude rats with well-established human head and neck cancer and NSCLC xenograft tumors for efficacy, toxicity, metastasis, and mechanistic studies.

Intetumumab significantly enhanced the efficacy of radiation in both human head and neck cancer FaDu and NSCLC A549 tumor models. The magnitude of sensitization was greater in these rat models than previously observed with the mouse tumor models, as evidenced by the higher tumor response rates. Although the tumor xenograft models studied in mice and rats differed, we did not previously observe any complete regressions of tumors from four different tumor models studied in mice, including a head and neck tumor model, treated with more frequent dosing of intetumumab (10 mg/kg, three doses per week in mice compared with weekly dose in rats). This was not surprising because in the rat tumor models, the antibody was able to bind to both \( \alpha_v \) integrin–expressing tumor cells and vascular endothelial cells, and exert direct effects on both.

A variety of mechanistic studies were performed to further elucidate the underlying mechanism of this effect. Microvessels in intetumumab-treated tumors were morphologically more regular and relatively uniformly distributed within the tumors. The combination of intetumumab and radiation resulted in a significant decrease in the microvessel density compared with radiation alone and was associated with morphologic changes indicative of altered vascular function. There was also a correlation between microvessel density and the level of apoptosis in treated tumors. EF5 staining of hypoxic cells was decreased by 40% in tumors treated with intetumumab alone and reduced by 54% in tumors treated with intetumumab plus radiation. Furthermore, microbubble-enhanced ultrasound imaging showed that intetumumab markedly increased tumor blood volume and perfusion rates, which were further enhanced, but to a lesser extent, by combining intetumumab with radiation. Jain (11) has reported that antiangiogenic agents can transiently normalize tumor vasculature and that this effect may be secondarily associated with changes in tumor perfusion and oxygenation. We hypothesize that intetumumab had a similar effect, which is also consistent with results from studies of a variety of other antiangiogenic agents that have been reported to affect microvessel density, morphology, and function and to enhance

Figure 3. Immunohistochemical analysis of apoptosis, vessel density, and oxygenation in FaDu xenograft tumors. Digital photographs were taken at \( \times40 \) magnification with a Leica microscope equipped with a digital camera. Right, quantification of apoptosis, CD31, and EF5 staining. Four fields per section per tumor were analyzed. Columns, mean of three tumors for each group; bars, SD.
tumor responses to radiation (5, 12, 13). Our previous study has shown that treatment with intetumumab inhibited the expression of the angiogenic marker vascular endothelial growth factor receptor in vascular endothelial cells as well as in tumor cells (5). Radiation, on the other hand, not only kills tumor cells and endothelial cells in tumors but also induces and activates the expression of a variety of proangiogenic and prosurvival factors. Treatment with intetumumab in combination with radiation could inhibit the radiation-induced overexpression of proangiogenic factors and angiogenesis in tumors. Taken together, these results suggest that intetumumab inhibited angiogenesis, normalized the microvessel morphology, increased the tumor perfusion rate and blood volume, and increased oxygenation, all of which were further enhanced by radiation, resulting in decreased tumor hypoxia/increased tumor pO₂ and, over time, in increased damage to the tumor microvasculature and increased tumor cell killing.

Although the antiangiogenic and radiosensitizing effects of intetumumab are not unique, intetumumab has the added advantage over many other antiangiogenic agents in development, such as inhibiting the development of metastases by targeting the αv integrin receptors and blocking its downstream cell adhesion signaling pathway (4). Here, we further show the ability of intetumumab to inhibit the subsequent development of pulmonary metastases in the NSCLC A549 model following either i.v. administration of tumor cells or spontaneous metastasis from established s.c. tumors. Metastasis of a primary tumor to distant sites is a complicated multistep process, involving dissociation of tumor cells from the original tumors, epithelial-mesenchymal transition, breach of the basement membrane, invasion of the extracellular matrix tissues, intravasation into preexisting and newly formed blood and lymph vessels (angiogenesis and lymphangiogenesis), transport through and extravasation from vessels, invasion, adhesion, establishment of disseminated cells at a secondary distant site, and proliferation (reviewed in refs. 14, 15). At each step, there are one or more physiologic barriers to the metastasis of tumor cells, such as anoikis, a type of cell death due to detachment or loss of cell adhesion. Studies have shown that integrins play a pivotal role in many steps of this metastatic process, especially in dissociation, invasion, adhesion, proliferation, and angiogenesis in both primary and distant secondary sites (16–20). Integrins, as the key cell surface receptors for cell-cell and cell–extracellular matrix interactions, sense and initiate the signaling of cell motility, invasion, and adhesion; interact with receptor tyrosine kinases; and activate downstream signaling of FAK and SRC family kinases (21). Treatment with intetumumab inactivates the FAK and paxillin docking protein by tyrosine dephosphorylation of the tyrosine residues, followed by the inhibition of invasion and motility of tumor cells in vitro (4). Furthermore, intetumumab has been reported to be more potent at inhibiting cell adhesion, motility, and invasion than other anti–αv-containing integrin antibodies, RGD mimetics, and small molecules (1, 4). Interaction of tumor cells with extracellular matrix via adhesion molecules is important for survival and metastasis of tumors and may play a pivotal role in resistance to radiation therapy (22, 23). In addition, the relative radioresistance of stem or stem-like metastatic tumor cells is an important clinical problem (24, 25) and contributes to the failure of conventional cytotoxic therapies. Therefore, one can hypothesize that intetumumab could both block homing of tumor cells to potential metastatic sites and radiosensitize these cells. These properties of intetumumab could potentially inhibit metastasis and facilitate eradication of these resistant tumor subpopulations by radiation, thereby increasing the efficacy of local tumor radiation therapy via multiple mechanisms.

Figure 4. Microbubble-enhanced ultrasound imaging of FaDu tumors in nude rats 2 d after treatment. Data are presented as the image intensity as a function of image frame (time). The first 100 frames were acquired before microbubble injection.
Agents that enhance the efficacy of radiation therapy are only beneficial if they do not similarly sensitize normal tissue to radiation therapy. Using the intestinal crypt cell assay, we were able to show that intetumumab alone had no detectable cytotoxic effect on crypt cell numbers or morphology and had no significant effect on the sensitivity of the crypt cells to radiation. This is very important because crypt cells are very radiosensitive, and the sensitivity of the intestines and rectum to radiation limits the dose of radiation that can safely be used to treat abdominal and pelvic tumors. In addition, there were no apparent histopathologic changes in lungs from rats treated with intetumumab either alone or in combination with radiation compared with untreated rats. Intetumumab was very well tolerated by the rats, with no significant weight loss or observable signs of toxicity when used alone or in combination with radiation therapy. It should be pointed out that there is a ubiquitous expression of αv integrins in normal tissues, and the binding of intetumumab to human αv integrins is greater than in rats. Therefore, caution should be used in extrapolating these safety and toxicity data from rats to human patients. However, data from a preclinical toxicity study in cynomolgus macaques showed that treatment with intetumumab produced no sign of toxicity and no histopathologic changes in any of the tissues examined (2). Data from two recently completed phase I clinical trials (6, 7) further showed that intetumumab was generally safe and well tolerated either alone or in combination with docetaxel in 6-week or prolonged treatment regimens. There were no dose-limiting toxicities reported in these studies.

In summary, these results are very encouraging and show that intetumumab can potentiate the efficacy of fractionated radiation therapy and inhibit metastasis in rats with human cancer xenograft tumors, without enhancing effects of radiation on intestinal crypt cells (normal tissue toxicity). These findings may have near-term translational potential for the treatment of solid tumors in patients using radiation therapy.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

Received 05/12/2010; revised 07/07/2010; accepted 07/17/2010; published OnlineFirst 09/14/2010.
References


Anti–αv Integrin Monoclonal Antibody Intetumumab Enhances the Efficacy of Radiation Therapy and Reduces Metastasis of Human Cancer Xenografts in Nude Rats

Shoucheng Ning, Junqiang Tian, Deborah J. Marshall, et al.

Cancer Res  Published OnlineFirst September 14, 2010.

Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-10-1639

Sign up to receive free email-alerts related to this article or journal.

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

To request permission to re-use all or part of this article, use this link http://cancerres.aacrjournals.org/content/early/2010/09/10/0008-5472.CAN-10-1639. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.